299 related articles for article (PubMed ID: 34547511)
41. Switch to ocrelizumab in MS patients treated with natalizumab in extended interval dosing at high risk of PML: A 96-week follow-up pilot study.
Santiago-Setien P; Barquín-Rego C; Hernández-Martínez P; Ezquerra-Marigomez M; Torres-Barquin M; Menéndez-Garcia C; Uriarte F; Jiménez-López Y; Misiego M; Sánchez de la Torre JR; Setien S; Delgado-Alvarado M; Riancho J
Front Immunol; 2023; 14():1086028. PubMed ID: 36817456
[TBL] [Abstract][Full Text] [Related]
42. Lack of specific T- and B-cell clonal expansions in multiple sclerosis patients with progressive multifocal leukoencephalopathy.
Bertoli D; Sottini A; Capra R; Scarpazza C; Bresciani R; Notarangelo LD; Imberti L
Sci Rep; 2019 Nov; 9(1):16605. PubMed ID: 31719595
[TBL] [Abstract][Full Text] [Related]
43. Anti-JCV serology during natalizumab treatment: Review and meta-analysis of 17 independent patient cohorts analyzing anti-John Cunningham polyoma virus sero-conversion rates under natalizumab treatment and differences between technical and biological sero-converters.
Schwab N; Schneider-Hohendorf T; Hoyt T; Gross CC; Meuth SG; Klotz L; Foley JF; Wiendl H
Mult Scler; 2018 Apr; 24(5):563-573. PubMed ID: 28847222
[TBL] [Abstract][Full Text] [Related]
44. JC virus load in cerebrospinal fluid and transcriptional control region rearrangements may predict the clinical course of progressive multifocal leukoencephalopathy.
Delbue S; Elia F; Carloni C; Tavazzi E; Marchioni E; Carluccio S; Signorini L; Novati S; Maserati R; Ferrante P
J Cell Physiol; 2012 Oct; 227(10):3511-7. PubMed ID: 22253012
[TBL] [Abstract][Full Text] [Related]
45. Prognostic significance of JC virus DNA levels in cerebrospinal fluid of patients with HIV-associated progressive multifocal leukoencephalopathy.
Bossolasco S; Calori G; Moretti F; Boschini A; Bertelli D; Mena M; Gerevini S; Bestetti A; Pedale R; Sala S; Sala S; Lazzarin A; Cinque P
Clin Infect Dis; 2005 Mar; 40(5):738-44. PubMed ID: 15714422
[TBL] [Abstract][Full Text] [Related]
46. Does risk stratification decrease the risk of natalizumab-associated PML? Where is the evidence?
Cutter GR; Stüve O
Mult Scler; 2014 Sep; 20(10):1304-5. PubMed ID: 24812045
[TBL] [Abstract][Full Text] [Related]
47. Is maraviroc useful in multiple sclerosis patients with natalizumab-related progressive multifocal leukoencephalopathy?
Scarpazza C; Prosperini L; Mancinelli CR; De Rossi N; Lugaresi A; Capobianco M; Moiola L; Naldi P; Imberti L; Gerevini S; Capra R
J Neurol Sci; 2017 Jul; 378():233-237. PubMed ID: 28566170
[TBL] [Abstract][Full Text] [Related]
48. Neuropsychological Disability in the Case of Natalizumab-Related Progressive Multifocal Leukoencephalopathy.
Lo Buono V; D'Aleo G; Cammaroto S; De Cola MC; Palmese F; Smorto C; Marino S; Venuti G; Sessa E; Rifici C; Corallo F
Medicina (Kaunas); 2022 Apr; 58(4):. PubMed ID: 35454389
[TBL] [Abstract][Full Text] [Related]
49. Longitudinal JCV serology in multiple sclerosis patients preceding natalizumab-associated progressive multifocal leukoencephalopathy.
Vennegoor A; van Rossum JA; Polman CH; Wattjes MP; Killestein J
Mult Scler; 2015 Oct; 21(12):1600-3. PubMed ID: 25662344
[TBL] [Abstract][Full Text] [Related]
50. Changes to anti-JCV antibody levels in a Swedish national MS cohort.
Warnke C; Ramanujam R; Plavina T; Bergström T; Goelz S; Subramanyam M; Kockum I; Rahbar A; Kieseier BC; Holmén C; Olsson T; Hillert J; Fogdell-Hahn A
J Neurol Neurosurg Psychiatry; 2013 Nov; 84(11):1199-205. PubMed ID: 23463870
[TBL] [Abstract][Full Text] [Related]
51. Early reduction of the splicing factor2/alternative splicing factor: a cellular inhibitor of the JC polyomavirus in natalizumab-treated MS patients long before developing progressive multifocal leukoencephalopathy.
Piu C; Ibba G; Bertoli D; Capra R; Uleri E; Serra C; Imberti L; Dolei A
J Neurovirol; 2020 Feb; 26(1):133-137. PubMed ID: 31468472
[TBL] [Abstract][Full Text] [Related]
52. Mutations in the John Cunningham virus VP1 gene could predispose to the development of progressive multifocal leukoencephalopathy in multiple sclerosis patients undergoing treatment with natalizumab.
Flores J; Anguiano O; Rivas-Alonso V; González-Conchillos H; Pérez-Saldivar M; Sotelo J; Magaña-Maldonado R; Quiñones S; Corona T; Olivares H; Hernández-González O; Martínez-Palomo A; Treviño I; Ordoñez G
Mult Scler Relat Disord; 2021 Nov; 56():103266. PubMed ID: 34555758
[TBL] [Abstract][Full Text] [Related]
53. Host cell virus entry mechanisms enhance anti-JCV-antibody switch in natalizumab-treated multiple sclerosis patients.
Achiron A; Miron G; Zilkha-Falb R; Magalashvili D; Dolev M; Stern Y; Gurevich M
J Neurovirol; 2016 Dec; 22(6):736-746. PubMed ID: 27170332
[TBL] [Abstract][Full Text] [Related]
54. Performance of PML diagnostic criteria in natalizumab-associated PML: data from the Dutch-Belgian cohort.
Wijburg MT; Warnke C; Barkhof F; Uitdehaag BMJ; Killestein J; Wattjes MP
J Neurol Neurosurg Psychiatry; 2019 Jan; 90(1):44-46. PubMed ID: 30100552
[TBL] [Abstract][Full Text] [Related]
55. Anti-JC virus antibodies in a large German natalizumab-treated multiple sclerosis cohort.
Trampe AK; Hemmelmann C; Stroet A; Haghikia A; Hellwig K; Wiendl H; Goelz S; Ziegler A; Gold R; Chan A
Neurology; 2012 May; 78(22):1736-42. PubMed ID: 22592369
[TBL] [Abstract][Full Text] [Related]
56. Cerebrospinal fluid analysis in 108 patients with progressive multifocal leukoencephalopathy.
Möhn N; Luo Y; Skripuletz T; Schwenkenbecher P; Ladwig A; Warnke C; Meuth SG; Wiendl H; Gross CC; Schröder C; Haghikia A; Stangel M
Fluids Barriers CNS; 2020 Oct; 17(1):65. PubMed ID: 33109245
[TBL] [Abstract][Full Text] [Related]
57. Study of the anti-JCV antibody levels in a Spanish multiple sclerosis cohort.
Dominguez-Mozo MI; Rus M; Santiago JL; Izquierdo G; Casanova I; Galan V; Garcia-Martinez MA; Arias-Leal AM; García-Montojo M; Pérez-Pérez S; Arroyo R; Alvarez-Lafuente R
Eur J Clin Invest; 2017 Feb; 47(2):158-166. PubMed ID: 28036121
[TBL] [Abstract][Full Text] [Related]
58. Progressive Multifocal Leukoencephalopathy Incidence and Risk Stratification Among Natalizumab Users in France.
Vukusic S; Rollot F; Casey R; Pique J; Marignier R; Mathey G; Edan G; Brassat D; Ruet A; De Sèze J; Maillart E; Zéphir H; Labauge P; Derache N; Lebrun-Frenay C; Moreau T; Wiertlewski S; Berger E; Moisset X; Rico-Lamy A; Stankoff B; Bensa C; Thouvenot E; Heinzlef O; Al-Khedr A; Bourre B; Vaillant M; Cabre P; Montcuquet A; Wahab A; Camdessanché JP; Tourbah A; Guennoc AM; Hankiewicz K; Patry I; Nifle C; Maubeuge N; Labeyrie C; Vermersch P; Laplaud DA;
JAMA Neurol; 2020 Jan; 77(1):94-102. PubMed ID: 31479149
[TBL] [Abstract][Full Text] [Related]
59. Analysis of cerebrospinal fluid and cerebrospinal fluid cells from patients with multiple sclerosis for detection of JC virus DNA.
Iacobaeus E; Ryschkewitsch C; Gravell M; Khademi M; Wallstrom E; Olsson T; Brundin L; Major E
Mult Scler; 2009 Jan; 15(1):28-35. PubMed ID: 18805840
[TBL] [Abstract][Full Text] [Related]
60. Radiological abnormalities in progressive multifocal leukoencephalopathy: Identifying typical and atypical imaging patterns for early diagnosis and differential considerations.
Soni N; Ora M; Mangla R; Singh R; Ellika S; Agarwal A; Meyers SP; Bathla G
Mult Scler Relat Disord; 2023 Sep; 77():104830. PubMed ID: 37418930
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
